The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys

British Journal of Pharmacology

Volumn 164, Issue 3, 2011, Pages 970-978

  Webster, Scott J ^a   Wilson, Christina A ^a   Lee, Chih Hung ^c   Mohler, Eric G ^c   Terry Jr , Alvin V ^a   Buccafusco, Jerry J ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

cognitive; dimebolin; drug; monkey; operant

Indexed keywords

DIMEBON; SCOPOLAMINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SINGLE DRUG DOSE; TASK PERFORMANCE; TREATMENT RESPONSE; WORKING MEMORY;

AGE FACTORS; ALZHEIMER DISEASE; ANIMALS; COGNITION DISORDERS; FEMALE; INDOLES; MACACA MULATTA; MALE; MEMORY, SHORT-TERM; PSYCHOMOTOR PERFORMANCE; SCOPOLAMINE HYDROBROMIDE;

EID: 80052559894     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01432.x     Document Type: Article

References (38)

1. Alexander SP, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC) 4th edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, et al,. (2001). Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann NY Acad Sci 939: 425-435. (Pubitemid 32620096)
3. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO, (2003). Mitochondria as a target for neurotoxins and neuroprotective agents. Ann NY Acad Sci 993: 334-344. discussion 345-9. (Pubitemid 36808462)
4. Bejar C, Wang RH, Weinstock M, (1999). Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur J Pharmacol 383: 231-240.
5. Birks J, (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev (1): CD005593.
6. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi MH, (2007). Forecasting the global burden of Alzheimer's disease. Johns Hopkins University Johns Hopkins University, Dept. of Biostatistics Working Papers, page 130.
7. de Bruin N, Pouzet B, (2006). Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval. Pharmacol Biochem Behav 85: 253-260. (Pubitemid 44772926)
8. Buccafusco JJ, (2008). Estimation of working memory in macaques for studying drugs for the treatment of cognitive disorders. J Alzheimers Dis 15: 709-720.
9. Buccafusco JJ, Terry Jr. AV, Webster SJ, Martin DM, Hohnadel EJ, Bouchard KA, et al,. (2008). The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant conditioning memory tasks for screening drug candidates. Psychopharmacology 199: 481-494. (Pubitemid 351938233)
10. Buccafusco JJ, Webster SJ, Terry Jr. AV, Kille N, Blessing D, (2009). Protracted cognitive effects produced by clonidine in Macaca Nemestrina performing a delayed matching task. Psychopharmacology 202: 477-485.
11. Carlsson CM, (2008). Lessons learned from failed and discontinued clinical trials for the treatment of Alzheimer's disease: future directions. J Alzheimers Dis 15: 327-338.
12. Cummings JL, (2004). Alzheimer's disease. N Engl J Med 351: 56-67.
13. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, et al,. (2008). Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372: 207-215. (Pubitemid 351978110)
14. Dunnett SB, (1985). Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats. Psychopharmacology (Berl) 87: 357-363. (Pubitemid 16225687)
15. Ebert U, Kirch W, (1998). Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest 28: 944-949. (Pubitemid 28521587)
16. Gellerman E, (1933). Chance ordering of alternating stimuli in visual discrimination. Pedagog Sem J Genetic Psychol 42: 206-208.
17. Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T, et al,. (2010). Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism. J Pharmacol Exp Ther 333: 748-757.
18. Grigorev VV, Dranyi OA, Bachurin SO, (2003). Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med 136: 474-477. (Pubitemid 39137308)
19. Grigor'ev VV, Garibova TL, Voronina TA, Litvinova SA, Bachurin SO, (2009). [Effects of chronic administration of dimebon on behavior and memory of SAMP 10 mice]. Eksp Klin Farmakol 72: 52-56.
20. Jackson WJ, Buccafusco JJ, (1991). Clonidine enhances delayed matching-to-sample performance by young and aged monkeys. Pharmacol Biochem Behav 39: 79-84.
21. Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER, et al,. Dimebon in Subjects With Huntington Disease (DIMOND) Investigators of the Huntington Study Group (2010). A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease. Arch Neurol 67: 154-160.
22. Lermontova NN, Lukoyanov NV, Serkova TP, Lukoyanova EA, Bachurin SO, (2000). Dimebon improves learning in animals with experimental Alzheimer's disease. Bull Exp Biol Med 129: 544-546.
23. Lermontova NN, Redkozubov AE, Shevtsova EF, Serkova TP, Kireeva EG, Bachurin SO, (2001). Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels. Bull Exp Biol Med 132: 1079-1083. (Pubitemid 34295938)
24. Lindner MD, Hogan JB, Hodges DB Jr, Orie AF, Chen P, Corsa JA, et al,. (2006). Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping. Psychopharmacology (Berl) 188: 629-640. (Pubitemid 46758973)
25. Lowenstein PR, Castro MG, (2009). Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Curr Gene Ther 9: 368-374.
26. McArthur RA, Gray J, Schreiber R, (2010). Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials. Curr Opin Investig Drugs 11: 740-760.
27. Paule MG, Bushnell PJ, Maurissen JP, Wenger GR, Buccafusco JJ, Chelonis JJ, et al,. (1998). Symposium overview: the use of delayed matching-to-sample procedures in studies of short-term memory in animals and humans. Neurotoxicol Teratol 20: 493-502. (Pubitemid 28511113)
28. Pfizer Press Release (2010). Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer's Disease Clinical Development Program. Obtained from.
29. Schaffhauser H, Mathiasen JR, Dicamillo A, Huffman MJ, Lu LD, McKenna BA, et al,. (2009). Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities. Biochem Pharmacol 78: 1035-1042.
30. Shannon HE, Peters SC, (1990). A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice. J Pharmacol Exp Ther 255: 549-553.
31. Simon R, (2008). Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility. Eur J Cancer 44: 2707-2713.
32. van der Staay FJ, Bouger PC, (2005). Effects of the cholinesterase inhibitors donepezil and metrifonate on scopolamine-induced impairments in the spatial cone field orientation task in rats. Behav Brain Res 156: 1-10. (Pubitemid 39330431)
33. Terry AV Jr, Buccafusco JJ, Borsini F, Leusch A, (2002). Memory-related task performance by aged rhesus monkeys administered the muscarinic M(1)-preferring agonist, talsaclidine. Psychopharmacology (Berl) 162: 292-300. Epub 2002 May 29. (Pubitemid 34762288)
34. Tishchenkova IF, Agapitova IV, Dorokhov VV, Bobroy VI, Dubrovina LYU, (1991). Experimental Study of Dimebon Kinetics. All-Union Scientific-Research Institute of Biotechnology, Moscow. Translated from Khimii-farmatsevticheskii Zhurnal, Vol. 25, No. 12, pp.13-15, December, 1991. Original article submitted December 12, 1990.
35. Woolley ML, Marsden CA, Fone KCF, (2004). 5-HT6 receptors. Curr Drug Targets CNS Neurol Disord 3: 59-79.
36. Wu J, Li Q, Bezprozvanny I, (2008). Evaluation of Dimebon in cellularmodel ofHuntington's disease. Mol Neurodegener 3: 15.
37. Youdim MBH, Buccafusco JJ, (2005a). CNS targets for multi-functional drugs in the treatment of neurodegenerative diseases. J Neural Transm 112: 519-537. (Pubitemid 40562085)
38. Youdim MBH, Buccafusco JJ, (2005b). Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacological Sci 26: 27-35. (Pubitemid 40052707)